- Home
- DRTS
as 11-13-2024 4:00pm EST
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. The Alpha CaRT technology of the company utilizes the therapeutic properties of alpha particles aiming to overcome, and harness for benefit for alpha radiation's range. The company derives maximum revenue from Israel.
| Founded: | 2015 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 158.4M | IPO Year: | N/A |
| Target Price: | $8.00 | AVG Volume (30 days): | 23.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.40 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.75 - $3.40 | Next Earning Date: | 11-22-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Alpha Tau Medical Ltd. News
DRTS Breaking Stock News: Dive into DRTS Ticker-Specific Updates for Smart Investing
GlobeNewswire
14 hours ago
Alpha Tau to Participate in Citi’s 2024 Global Healthcare Conference and Piper Sandler’s 36th Annual Healthcare Conference
Simply Wall St.
12 days ago
Discover Alpha Tau Medical And 2 Other US Penny Stocks
GlobeNewswire
24 days ago
Alpha Tau Announces Acceptance Into FDA’s Total Product Life Cycle Advisory Program to Accelerate Market Access to Alpha DaRT® for Patients with Recurrent Glioblastoma Multiforme
TipRanks
a month ago
Alpha Tau’s Alpha DaRT Advances Lung Cancer Treatment
GlobeNewswire
a month ago
Alpha Tau Treats First Patient with Recurrent Lung Cancer
Medical Device Network
2 months ago
FDA approves study of Alpha Tau’s Alpha DaRT for recurrent cSCC treatment
MT Newswires
2 months ago
Alpha Tau Medical Gets FDA Approval to Start Alpha DaRT Cancer Therapy Study
GlobeNewswire
2 months ago
Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC
Compare DRTS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DRTS Alpha Tau Medical Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.